Compare HKPD & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | SPHL |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | Hong Kong | Singapore |
| Employees | N/A | 73 |
| Industry | Other Pharmaceuticals | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.1M |
| IPO Year | 2024 | 2023 |
| Metric | HKPD | SPHL |
|---|---|---|
| Price | $1.62 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 484.2K | ★ 2.1M |
| Earning Date | 08-07-2026 | 09-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.36 |
| 52 Week High | $2.42 | $25.11 |
| Indicator | HKPD | SPHL |
|---|---|---|
| Relative Strength Index (RSI) | 62.53 | 50.24 |
| Support Level | $0.29 | $2.18 |
| Resistance Level | $2.42 | $2.68 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 25.94 | 17.58 |
Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong. It operates through two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, referred to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, referred to as the Procurement and Distribution division. Its main business provides one-stop services for merchants engaged in cross-border pharmaceutical e-commerce, including OTC wholesale, import and export, warehousing, packaging, customs clearance and delivery to final destinations, forming a closed loop of pharmaceutical cross-border e-commerce supply chain.
Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.